Conclusion
Our study demonstrated that Veregen® is not only safe but results in at least a partial clinical resolution of uVIN lesions in all patients. Furthermore, we show that Veregen® treatment also offers symptoms improvement and a potentially better quality of life. Together, our result suggests that further phase 3 randomised controlled study is warranted to evaluate the efficacy of Veregen® in a sizeable multicentre setting to include patients with primary and recurrence disease. Lastly, as Veregen® ointment is relatively well tolerated with minimal side effects, there is a possibility for increasing treatment duration beyond currently recommended 16 weeks, as prolonged treatment may lead to a histological resolution of uVIN.